FT News Feed
Clarifying Fetal Tissue Policy Contradictions
Father Tad writes about the pharmaceutical made by Regeneron taken by President Trump following his infection with COVID-19 and addresses successes and failures in the administration's fetal tissue policies.
If the president and his administration are to be credibly accused of inconsistency with respect to their stance on using fetal cell lines from abortions, it would not be because the president personally received a dose of Regeneron’s drug, but rather because of a very different ethical failure: his administration’s channeling of hundreds of millions of dollars of taxpayer funds directly into the development of COVID-19 vaccines that utilize abortion-derived cells for their production. See: Clarifying Fetal Tissue Policy Contradictions